Experimental tumor inhibitory and toxic properties of the mitomycin A analogue 7-(2-hydroxyethoxy) mitosane (BMY-25551).
BMY-25551, 7-(2-hydroxyethoxy)mitosane, was selected from a series of mitomycin A (MMA) analogues for more detailed study. As with other members of this class, it was shown to be 8 to 20 times more potent than mitomycin C (MMC) in cytotoxicity to murine and human tumor cell lines in vitro, in causing DNA cross links in vitro, and in dose levels for tumor inhibition in vivo. BMY-25551 appeared to be more effective in tumor inhibition than MMC against P388 leukemia and B16 melanoma in mice and comparable to MMC against L1210 leukemia and Madison 109 lung carcinoma. BMY-25551 was also comparable to MMC in hematologic depression in mice. Factors affecting its possible utility in humans are discussed.
Bradner
W T
WT
Pharmaceutical Research Institute, Bristol-Myers Squibb Company, Syracuse, NY 13221-4755.
Catino
J J
JJ
Long
B H
BH
Rose
W C
WC
Schurig
J E
JE
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects*; D003110:Colonic Neoplasms; D004249:DNA Damage; D004273:DNA, Neoplasm / Q000187:drug effects / Q000528:radiation effects; D004354:Drug Screening Assays, Antitumor; D005720:Gamma Rays; D006801:Humans; D007624:KB Cells; D008175:Lung Neoplasms; D008546:Melanoma, Experimental; D051379:Mice; D016685:Mitomycin / Q000494:pharmacology*; D008937:Mitomycins / Q000494:pharmacology
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D008937:Mitomycins; C075426:7-(2-hydroxyethoxy)mitosane; D016685:Mitomycin